MEDMEN CANADA WILL HAVE ACCESS TO THE (CRONOS) PRODUCTION FACILITIES.

position in cannabis-industry financial markets. It follows a vote of confidence the company received from U.S. investors and regulators in late February, when it became the first Canadian cannabis company to list on the Nasdaq exchange.

It also follows two bought deals in the last six months, with $16.5 million raised in November and $46 million raised in January.

Despite their success in from the latest financing deal on international capital expenditures. It is currently building a greenhouse and extraction lab facility in Israel, and recently announced plans for a facility in Australia.

In December, it sent its first shipment of medical cannabis to Germany, as part of a deal with German pharmaceutical manufacturer G. Pohl-Boskamp GmbH.

It intends to use “the remaining net proceeds of the offering for general working capital purposes, including working capital for the Company’s international operations, and as capital on hand for potential new investment opportunities,” the company said in a news release on Thursday.

On Monday the company announced a partnership with the MM Enterprises USA, LLC (MedMen Enterprises), a large U.S. dispensary chain with operations in several states. The 50-50 joint venture, which will be called MedMen Canada Inc., will bring MedMen-branded products to Canada along with retail stores in the jurisdictions allowing private retail.

“MedMen Canada will have access to the (Cronos) production facilities while leveraging MedMen’s brand recognition. In addition, the Company will be leveraging its regulatory expertise and know-how to obtain the requisite licences, approvals and permits from Health Canada for MedMen Canada to commence its operations,” Cronos said in its prospectus.